Smart Drug Design Through Fragment-Based Approaches Will Drive Growth In The Global Fragment Based Drug Discovery Market

The fragment based drug discovery approach involves screening libraries of very small molecules called fragments that bind to targets of therapeutic interest with low molecular weight and high binding efficiency. These fragments act as starting points for developing potential drug candidates. Compared to high-throughput screening, fragment-based methods require smaller libraries that can be easily synthesized and screened. Fragment hits have low affinity but high efficiency that improves the probability of growing them into potent and selectiveligands through structure based drug design.

The Global Fragment Based Drug Discovery Market is estimated to be valued at US$ 0.795 Bn in 2024 and is expected to exhibit a CAGR of 15% over the forecast period 2024-2031.

Key players operating in the fragment based drug discovery market include Astex Pharmaceuticals, Beactica AB, Charles River Laboratories International, Inc., Evotec AG, and Alveus Pharmaceuticals Pvt. Ltd.

Key Takeaways

Key players operating in the fragment based drug discovery market are focusing on expanding their fragment libraries and enhancing screening capabilities to identify novel hits. For instance, in 2022, Astex Pharmaceuticals significantly expanded its fragment library collection to over 450,000 fragments to enable robust hit identification.

The growing incidence of chronic diseases coupled with rising drug discovery and development activities is fueling the demand for fragment-based techniques. Fragment based screening allows developing biologically relevant leads with superior physiochemical and pharmacological properties compared to high-throughput screening.

Technological advancements in biophysical methods such as NMR, crystallography, mass spectrometry and computational modeling tools have widened the application scope of fragment based approaches in hit identification and optimization stages of drug R&D. In 2023, Evotec AG introduced the PanOmics platform to integrate omics data for enhancing fragment hits using systems chemical biology approaches.

Market Trends

De-risking drug candidates: Fragment based screening enables identifying low risk hits bound to attractive regions of target proteins with high efficiency. By optimizing these fragments, drug candidates with lower biological and chemical liability can be developed.

Integrating biophysical methods: Combining multiple biophysical techniques such as X-ray crystallography, NMR spectroscopy, SPR, and SBM provides comprehensive structural and binding information for fragment evolutions and optimization.

Leveraging artificial intelligence: Machine learning and deep learning based computational tools are being increasingly used to process, analyze and interpret large experimental datasets generated through fragment screening campaigns to facilitate hit discovery and design.

Market Opportunities

Growing collaboration between pharmaceutical companies and academic research institutes is expected to boost knowledge sharing and resource optimization for fragment libraries creation and screening. Moreover, increasing R&D investments and funding support from governments and private organizations will facilitate clinical research on fragment-derived drug candidates.

Impact Of COVID-19 On Global Fragment Based Drug Discovery Market:

The COVID-19 pandemic has significantly impacted the Global Fragment Based Drug Discovery Market. During the initial lockdown phase, drug discovery activities were disrupted as research labs and facilities were shut down to curb the virus spread. This led to delays in lab experiments, screening programs and drug development timelines. Researchers faced difficulties in accessing facilities for fragment screening, biophysical analyses and hit validation studies. Supply chain disruptions also created shortages of laboratory consumables and reagents required for fragment based screening assays.

However, as restrictions eased in late 2020, companies resumed operations with new safety protocols. Many shifted their focus towards developing treatments and vaccines for COVID-19. Fragments screening emerged as a promising approach for rapidly identifying potent antiviral hits against the SARS-CoV-2 virus. Several academic and pharmaceutical institutions employed their expertise and infrastructure in fragment based drug design to speed up the search for COVID-19 therapies. Government and private funding also increased for coronavirus drug development projects utilizing fragment screening techniques.

Going forward, companies are expected to leverage learnings from the pandemic. More efficient hybrid models blending onsite and remote working may be adopted. Fragment screening capabilities will be expanded to enable rapid response against future health emergencies. Enhanced collaborations between industry and academia can help expedite drug discovery programs. Overall, with resurgence plans and improved resilience, the long-term impact of COVID-19 on the fragmented based drug discovery market is expected to be positive.

Geographical Regions Of Concentrated Market Value:

The global fragmented based drug discovery market in terms of value is highly concentrated in North American and European countries. The United States holds the largest market share currently due to strong presence of leading pharmaceutical and biotechnology companies. Many top players have their core research and development centres located in the US and are involved in internal and collaborative fragment screening programs. Europe is also a major revenue generator owing to substantial investments in drug discovery research by both private sector and government research councils in countries like Germany, United Kingdom and France.

Fastest Growing Region:

The Asia Pacific region is anticipated to experience the highest growth in the global fragmented based drug discovery market over the forecast period. Factors such as increasing government focus on enhancing domestic innovation, rising biopharmaceutical industry investments, and growing skilled workforce availability are fueling market expansion in Asia Pacific. Countries like China, India and South Korea are emerging hubs for low-cost high quality contract research and manufacturing. This is attracting several multinational companies to establish fragment screening centers and collaborations in Asia to tap growth opportunities. Additionally, improving Intellectual Property (IP) frameworks and favorable business policies will further support market penetration of fragmented based drug discovery technologies across Asia Pacific.

Get more insights on this topic: https://www.trendingwebwire.com/global-fragment-based-drug-discovery-market-is-estimated-to-witness-high-growth-owing-to-technological-advancement-in-fragment-based-screening-techniques/

About Author:

Priya Pandey is a dynamic and passionate editor with over three years of expertise in content editing and proofreading. Holding a bachelor's degree in biotechnology, Priya has a knack for making the content engaging. Her diverse portfolio includes editing documents across different industries, including food and beverages, information and technology, healthcare, chemical and materials, etc. Priya's meticulous attention to detail and commitment to excellence make her an invaluable asset in the world of content creation and refinement. (LinkedIn - https://www.linkedin.com/in/priya-pandey-8417a8173/)

What Are The Key Data Covered In This Global Fragment Based Drug Discovery Market Report?

:- Market CAGR throughout the predicted period

:- Comprehensive information on the aspects that will drive the Global Fragment Based Drug Discovery Market's growth between 2024 and 2031.

:- Accurate calculation of the size of the Global Fragment Based Drug Discovery Market and its contribution to the market, with emphasis on the parent market

:- Realistic forecasts of future trends and changes in consumer behaviour

:- Global Fragment Based Drug Discovery Market Industry Growth in North America, APAC, Europe, South America, the Middle East, and Africa

:- A complete examination of the market's competitive landscape, as well as extensive information on vendors

:- Detailed examination of the factors that will impede the expansion of Global Fragment Based Drug Discovery Market vendors

FAQ’s

Q.1 What are the main factors influencing the Global Fragment Based Drug Discovery Market?

Q.2 Which companies are the major sources in this industry?

Q.3 What are the market’s opportunities, risks, and general structure?

Q.4 Which of the top Global Fragment Based Drug Discovery Market companies compare in terms of sales, revenue, and prices?

Q.5 Which businesses serve as the Global Fragment Based Drug Discovery Market’s distributors, traders, and dealers?

Q.6 How are market types and applications and deals, revenue, and value explored?

Q.7 What does a business area’s assessment of agreements, income, and value implicate?

*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it